Wyeth RotaShield Coverage Has "No Return" On Investment, Plan Exec Says
Executive Summary
Wyeth-Ayerst's recently launched rotavirus vaccine RotaShield may not be cost-effective for a health care plan to cover, Penn-State Geisinger Health Plan VP-Pharmacy Services Otto Wolke suggested Oct. 9 at the Academy of Managed Care Pharmacy educational conference in Chicago.